Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the study drug, called Vactosertib, is safe and
determine what the best dose is to treat future patients when given in combination with
pomalidomide (POM). The study will also look to see if it has any effect on multiple myeloma,
when given in combination with POM.